Biotech Matters

Author: Bluestar BioAdvisors

Bluestar BioAdvisors team shares insights on drug pipelines and predicts industry trends. Each episode is hosted by a senior member of our New York City based life sciences consulting firm. The host is typically joined by an external expert guest, with whom the host expands on their experiences providing insights and recommendations for industry leaders and emergent innovators, and translating the data of today into the implications for business of science of tomorrow.
Be a guest on this podcast

Language: en-us

Genres: Life Sciences, Science

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

Ep. 7 - Heading to Houston: What We're Looking Forward to at ASN Kidney Week 2025 (with Dr. Pietro Canetta)
Episode 7
Monday, 3 November, 2025

Bluestar is once again heading to ASN Kidney Week, this time in Houston, TX. Since our last episode, Otsuka, the manufacturer of sibeprenlimab, announced that the FDA has granted Priority Review of their BLA application; its PDUFA date is November 28th of this year. Additionally, Vera Therapeutics, the manufacturer of atacicept put out a press release this past summer that the ORIGIN Phase 3 trial met its primary endpoint of reduction in proteinuria (UPCR); participants receiving atacicept achieved a 46% reduction from baseline, and 42% reduction compared to placebo at week 36 (p